New clinical trial studies the use of avelumab in patients with recurrent thymoma and thymic carcinoma

patient thanking his doctor

Thymoma and thymic carcinoma are cancers that originate from the thymus, a small gland that lies between the lungs and just above the heart. The thymus helps in the development of white blood cells and generates tolerance to self antigens. A new study uses immunotherapy for patients whose thymoma or thymic carcinoma has progressed after standard treatments. Arun Rajan, M.D., of the Thoracic and GI Oncology Branch, is leading this study in which the immunotherapy drug Avelumab, an immune checkpoint inhibitor, blocks a natural “off switch” and activates T cells into attacking tumor cells. For more information on this clinical trial:

Summary Posted: Sat, 04/01/2017